Literature DB >> 1165140

Problems and solutions to single-dose testing of analgesics: comparison of propoxyphene, codeine, and fenoprofen.

S O Waife, C M Gruber, B E Rodda, J F Nash.   

Abstract

Discrepancies exist between reports arising from single-dose and multiple-dose studies intended to compare the efficacy of oral analgesics. D Differences in the pharmacokinetic characteristics of these drugs account for much of the discord. Codeine and fenoprofen rapidly achieve their ultimate plasma equilibrium levels (on a q. 6h. schedule), whereas, propoxyphene requires a longer period, doubtless due to its longer half-life and proportionately smaller maintenance dose. If the drugs are not to be compared during the steady state, then administration of appropriate loading doses permits satisfactory single dose comparisons at steady-state concentrations.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1165140

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Biopharm        ISSN: 0340-0026


  4 in total

1.  Effects of a mu-opioid receptor agonist (codeine phosphate) on visuo-motor coordination and dynamic visual acuity in man.

Authors:  C M Bradley; A N Nicholson
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

Review 2.  Dextropropoxyphene overdose. Epidemiology, clinical presentation and management.

Authors:  A A Lawson; D B Northridge
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Nov-Dec

Review 3.  Dextropropoxyphene overdosage. Pharmacological considerations and clinical management.

Authors:  R J Young
Journal:  Drugs       Date:  1983-07       Impact factor: 9.546

4.  Single- and multiple-dose pharmacokinetics of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) compared with immediate-release hydrocodone bitartrate/ibuprofen and immediate-release tramadol HCl/acetaminophen.

Authors:  Krishna Devarakonda; Kenneth Kostenbader; Michael J Giuliani; Jim L Young
Journal:  J Pain Res       Date:  2015-09-30       Impact factor: 3.133

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.